Company: SRPT
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000950170-25-029973
Chunk: 481

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-02-28
Form: 10-K
Item: Item 9A
Chunk 481
---

        Adjustments and reconciling items

        —

        —

        —

        Consolidated net income (loss)
         
        $
        235,239

        $
        (535,977
        )
         
        $
        (703,488
        )
       
       (a) Research and development-other includes professional services, up-front, milestone, and other expenses, pre-clinical expenses and research and other expenses.(b) Selling, general and administrative-other includes professional services and other expenses.(c) Other segment items included in segment net income (loss) include accretion of investment discount, net, change in fair value of derivatives and other, net, as well as the items separately presented and not defined as significant expenses below.Significant expense categories that are regularly provided to the CODM include cost of sales (excluding amortization of in-licensed rights), compensation and other personnel expenses, manufacturing expenses, clinical trial expenses, facility- and technology-related expenses, research and development- other and selling, general and administrative- other. The other expense or income information are other segment items and include separate presentation of interest expense, income tax expense, depreciation and amortization, stock-based compensation, which are included in the measure of segment income (loss) but are not significant segment expenses.Assets provided to the CODM for the single segment are consistent with those reported on the consolidated balance sheets.

22. COMMITMENTS AND CONTINGENCIESManufacturing ObligationsThe Company has entered into long-term contractual arrangements from time to time for the provision of goods and services. The following table presents non-cancelable contractual obligations arising from long-term contractual arrangements, including obligations related to leases embedded in certain supply agreements: 

F-40

        As of December 31, 2024

        (in thousands)

        2025
         
        $
        943,067

        2026

        141,233

        2027

        79,860

        2028

        72,341

        Total manufacturing commitments*
         
        $
        1,236,501

      * Total manufacturing commitments include the Catalent Agreement (defined below), for which the Company determined has a lease embedded in it and, as such, has ROU assets and lease liabilities recorded on the consolidated balance sheets as of December 31, 2024. Thermo Fisher Scientific, Inc. The Company entered into a development, commercial manufacturing, and supply agreement as related to the Company's adherent